ライフサイエンスコーパス: myelin-oligodendrocyte glycoprotein

1 yelin basic protein, proteolipid protein, or myelin oligodendrocyte glycoprotein.

2 ntal autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein.

3 is severity by limiting central tolerance to myelin oligodendrocyte glycoprotein.

4 myelin-specific genes (myelin basic protein, myelin oligodendrocyte glycoprotein, 2',3'-cyclic-nucleo

5 The adoptive transfer of myelin oligodendrocyte glycoprotein(33-35)-sensitized B1

6 hanges in the CNS of NOD mice immunized with myelin oligodendrocyte glycoprotein 35-55 in CFA.

7 In vitro restimulation of splenocytes by myelin oligodendrocyte glycoprotein 35-55 peptide from t

8 Increasing the immunization dose of myelin oligodendrocyte glycoprotein 35-55 peptide, a mod

9 Subsequent immunization with myelin oligodendrocyte glycoprotein 35-55 peptide, which

10 er, EAE was induced by immunization with the myelin oligodendrocyte glycoprotein 35-55 peptide.

11 pared with that of control T cells following myelin oligodendrocyte glycoprotein 35-55 restimulation

12 In vitro Ag recall responses of myelin oligodendrocyte glycoprotein 35-55-immunized FABP

13 diabetes, we found them more susceptible to myelin oligodendrocyte glycoprotein 35-55-induced EAE co

14 Adoptive transfer of myelin oligodendrocyte glycoprotein 35-55-specific IRAK4

15 nt of young males inhibited proliferation of myelin oligodendrocyte glycoprotein 35-55-specific T cel

16 Adoptively transferred myelin oligodendrocyte glycoprotein 35-55-specific T cel

17 ays and then immunized with specific antigen myelin oligodendrocyte glycoprotein 35-55.

18 kly within the spleen, but not CNS following myelin oligodendrocyte glycoprotein(35-55) immunization,

19 dy that the generation of these effectors in myelin oligodendrocyte glycoprotein(35-55)-induced exper

20 In cocultures of murine myelin oligodendrocyte glycoprotein(35-55)-specific CD4+

21 A/IFN-gamma double reporter mouse and I-A(b)/myelin oligodendrocyte glycoprotein 38-49 tetramer, we s

22 CD8(+) T cells recognize the myelin peptide myelin oligodendrocyte glycoprotein 40-54 (MOG40-54) bot

23 experiments, we found that highly purified, myelin oligodendrocyte glycoprotein Ag-specific Th17 cel

24 on EAE induction by active immunization with myelin oligodendrocyte glycoprotein amino acids 35-55 (M

25 P4-IgG, pathogenetic serum IgG antibodies to myelin oligodendrocyte glycoprotein, an antigen in the o

26 th a sequence relationship between BTNL2 and myelin oligodendrocyte glycoprotein, an autoantigen asso

27 Agouti rats by immunization with recombinant myelin oligodendrocyte glycoprotein and adjuvant.

28 shed EAE by covaccination with the genes for myelin oligodendrocyte glycoprotein and IL-4.

29 utaneous immunization with recombinant human myelin oligodendrocyte glycoprotein and then Ab once wee

30 e of antibodies recognizing the autoantigen, myelin oligodendrocyte glycoprotein and tumour target, H

31 d controls) by the subcutaneous injection of myelin oligodendrocyte glycoprotein, and after disease o

32 Molecules such as BTN3A1 (CD277), myelin oligodendrocyte glycoprotein, and mouse Skint1 an

33 g myelin basic protein, proteolipid protein, myelin oligodendrocyte glycoprotein, and myelin-associat

34 o the host mice supports suppression of both myelin oligodendrocyte glycoprotein- and myelin basic pr

35 Foxp3 also was observed during priming with myelin oligodendrocyte glycoprotein, another target neur

36 gainst aquaporin-4 (AQP4-Abs), but recently, myelin-oligodendrocyte glycoprotein antibodies (MOG-Abs)

37 Thus, we suggest that diagnoses such as myelin-oligodendrocyte glycoprotein antibody disease, mu

38 Myelin-oligodendrocyte glycoprotein antibody-positive pa

39 samples against four neurologic surface Ags (myelin oligodendrocyte glycoprotein, aquaporin 4, acetyl

40 elin basic protein, proteolipid protein, and myelin oligodendrocyte glycoprotein by immunostaining of

41 myelin basic protein, and to a lesser extent myelin oligodendrocyte glycoprotein, can serve as MSP su

42 chronic, nonremitting, paralytic disease in myelin oligodendrocyte glycoprotein-challenged C57BL/6 m

43 D1(G93A) mice were significantly depleted in myelin-oligodendrocyte glycoprotein compared with those

44 iously shown that the 2D2 TCR recognizes the myelin oligodendrocyte glycoprotein epitope (MOG)35-55 a

45 self-epitopes such as has been suggested for myelin oligodendrocyte glycoprotein epitope 35-55 (MOG35

46 argely confined to induction with either the myelin oligodendrocyte glycoprotein epitope MOG(35-55) o

47 In a pattern-II-type focal myelin oligodendrocyte glycoprotein-experimental autoimm

48 PKCtheta-deficient mice immunized with myelin oligodendrocyte glycoprotein failed to develop ce

49 E mice were given subcutaneous injections of myelin oligodendrocyte glycoprotein fragment1-125 emulsi

50 ment of PPAR-beta to the promoter of PLP and myelin oligodendrocyte glycoprotein genes in human oligo

51 autoimmune encephalomyelitis was induced by myelin-oligodendrocyte glycoprotein immunization in fema

52 ack of CNS inflammation and demyelination in myelin oligodendrocyte glycoprotein-immunized Def6(-/-)

53 Anti-myelin oligodendrocyte glycoprotein immunoglobulin G (MO

54 We evaluated the seroprevalence of myelin oligodendrocyte glycoprotein immunoglobulin G1 (M

55 une encephalomyelitis (EAE) was induced with myelin oligodendrocyte glycoprotein in humanized HLA-DR2

56 myelin-derived Ags (myelin basic protein and myelin oligodendrocyte glycoprotein) in palatine tonsils

57 CD3-specific antibody-mediated prevention of myelin oligodendrocyte glycoprotein-induced acute experi

58 D1480 treatment inhibits disease severity in myelin oligodendrocyte glycoprotein-induced classical an

59 y that deletion of the C3aR is protective in myelin oligodendrocyte glycoprotein-induced EAE in C57BL

60 d AZD8797 treatment in Dark Agouti rats with myelin oligodendrocyte glycoprotein-induced EAE resulted

61 We studied a mouse model of myelin oligodendrocyte glycoprotein-induced EAE treated

62 cells that present Ag within the CNS during myelin oligodendrocyte glycoprotein-induced EAE, with th

63 ice was sufficient to reduce the severity of myelin oligodendrocyte glycoprotein-induced experimental

64 Also, in a model of myelin oligodendrocyte glycoprotein-induced experimental

65 ted viral (AAV) system in the mouse model of myelin oligodendrocyte glycoprotein-induced experimental

66 ell-mediated autoimmune diseases, we studied myelin oligodendrocyte glycoprotein-induced experimental

67 ne demyelinating model of multiple sclerosis-myelin oligodendrocyte glycoprotein-induced experimental

68 also developed similar levels of disease in myelin oligodendrocyte glycoprotein-induced experimental

69 In an animal model of MS, active myelin oligodendrocyte glycoprotein-induced experimental

70 iorates neurological deficit and severity of myelin oligodendrocyte glycoprotein-induced experimental

71 use the murine model of the 35-55 peptide of myelin oligodendrocyte glycoprotein-induced experimental

72 Myelin-oligodendrocyte glycoprotein-induced experimental

73 y, the adoptive transfer of CD31-conditioned myelin oligodendrocyte glycoprotein-loaded DCs carried i

74 ) premyelinating and myelin basic protein(+)/myelin oligodendrocyte glycoprotein(+) mature oligodendr

75 ats pre-immunized with a subclinical dose of myelin oligodendrocyte glycoprotein mimicked the patholo

76 (CYM-5442) at the onset of clinical signs in myelin oligodendrocyte glycoprotein MOG(35-55)- induced

77 this question, we analyzed Qa-1 epitopes in myelin oligodendrocyte glycoprotein (MOG that is a prote

78 ncreased Th17 cell polarization in vivo upon myelin oligodendrocyte glycoprotein (MOG(35-55)) peptide

79 Here, we subjected PACAP-deficient mice to myelin oligodendrocyte glycoprotein (MOG(35-55))-induced

80 Using a myelin oligodendrocyte glycoprotein (MOG(35-55))-induced

81 ll activation, and promote the generation of myelin oligodendrocyte glycoprotein (MOG(35-55))-specifi

82 ng oral administration and immunization with myelin oligodendrocyte glycoprotein (MOG(35-55)).

83 hich T and B cells overexpress receptors for myelin oligodendrocyte glycoprotein (MOG) (referred to a

84 Oral administration of encephalitogenic myelin oligodendrocyte glycoprotein (MOG) 35-55 peptide

85 We mucosally administered myelin oligodendrocyte glycoprotein (MOG) 35-55 peptide

86 at expresses the alpha- and beta-chains of a myelin oligodendrocyte glycoprotein (MOG) 35-55-reactive

87 n this study, we demonstrate that individual myelin oligodendrocyte glycoprotein (MOG) 35-55-specific

88 f CD43 also affected cytokine production, as myelin oligodendrocyte glycoprotein (MOG) 35-55-specific

89 istry for two strongly down-regulated genes, myelin oligodendrocyte glycoprotein (Mog) and ermin (Erm

90 ctive CD4(+) T cell populations specific for myelin oligodendrocyte glycoprotein (MOG) and lymphocyti

91 Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies (MO

92 Investigations of myelin oligodendrocyte glycoprotein (MOG) antibodies are

93 Myelin oligodendrocyte glycoprotein (MOG) antibodies hav

94 mpare clinical features, disease course, and myelin oligodendrocyte glycoprotein (MOG) antibody (Ab)

95 Autoantibodies against myelin oligodendrocyte glycoprotein (MOG) are associated

96 In particular, antibodies to myelin oligodendrocyte glycoprotein (MOG) are elevated i

97 antibodies targeting conformationally intact myelin oligodendrocyte glycoprotein (MOG) are found in d

98 Ig-proteolipid protein (PLP) 1 and Ig-myelin oligodendrocyte glycoprotein (MOG) are Ig chimera

99 on of antibodies against folded or denatured myelin oligodendrocyte glycoprotein (MOG) by selective u

100 Autoantibodies to myelin oligodendrocyte glycoprotein (MOG) can induce dem

101 Indeed, when Ig-myelin oligodendrocyte glycoprotein (MOG) carrying the M

102 with the extracellular Ig-like domain of rat myelin oligodendrocyte glycoprotein (MOG) developed expe

103 injected i.v. with an autoantigen peptide of myelin oligodendrocyte glycoprotein (MOG) developed less

104 otect a proteolysis-sensitive immunodominant myelin oligodendrocyte glycoprotein (MOG) epitope (resid

105 encephalomyelitis (EAE) can be achieved with myelin oligodendrocyte glycoprotein (MOG) fused to reovi

106 cognizing conformation-dependent epitopes of myelin oligodendrocyte glycoprotein (MOG) have a demyeli

107 Although Abs specific for myelin oligodendrocyte glycoprotein (MOG) have been dete

108 -FU-resistant CD11b(-)CD45(-) MSCs 6 d after myelin oligodendrocyte glycoprotein (MOG) immunization c

109 Using myelin oligodendrocyte glycoprotein (MOG) immunization,

110 cells to enhance EAE severity resulting from myelin oligodendrocyte glycoprotein (MOG) immunization.

111 Myelin oligodendrocyte glycoprotein (MOG) is a central n

112 Myelin oligodendrocyte glycoprotein (MOG) is an Ag prese

113 Myelin oligodendrocyte glycoprotein (MOG) is an encephal

114 Myelin oligodendrocyte glycoprotein (MOG) is an integral

115 We demonstrate that processing of myelin oligodendrocyte glycoprotein (MOG) is required fo

116 Myelin oligodendrocyte glycoprotein (MOG) is, quantitati

117 ion of C57BL/6 mice with either rat or human myelin oligodendrocyte glycoprotein (MOG) leads to exper

118 ype littermates, following immunization with myelin oligodendrocyte glycoprotein (MOG) p35-55 peptide

119 We induced EAE with myelin oligodendrocyte glycoprotein (MOG) peptide 35-55

120 or C57BL/6NOS2(-/)- mice were immunized with myelin oligodendrocyte glycoprotein (MOG) peptide 35-55

121 et and a more chronic form of EAE induced by myelin oligodendrocyte glycoprotein (MOG) peptide 35-55

122 ficient (Nrf2(-/-)) mice were immunized with myelin oligodendrocyte glycoprotein (MOG) peptide 35-55

123 In BALB/c mice immunized with myelin oligodendrocyte glycoprotein (MOG) peptide 35-55,

124 nd that PKC theta-/- mice immunized with the myelin oligodendrocyte glycoprotein (MOG) peptide MOG(35

125 ignificantly lower incidence and severity of myelin oligodendrocyte glycoprotein (MOG) peptide-induce

126 z show impaired recovery from EAE induced by myelin oligodendrocyte glycoprotein (MOG) peptide.

127 esistant to EAE induced by immunization with myelin oligodendrocyte glycoprotein (MOG) peptide.

128 row (BM) transduced with retrovirus encoding myelin oligodendrocyte glycoprotein (MOG) promotes disea

129 C57Bl/6 mice injected with myelin oligodendrocyte glycoprotein (MOG) received daily

130 To address this, we used myelin oligodendrocyte glycoprotein (MOG) T-cell recepto

131 After immunization with myelin oligodendrocyte glycoprotein (MOG) there was a pr

132 ergic encephalomyelitis when treated with Ig-myelin oligodendrocyte glycoprotein (MOG) tolerogen, an

133 antibodies to NMDAR, aquaporin-4 (AQP4), and myelin oligodendrocyte glycoprotein (MOG) was performed

134 T-bet-deficient mice immunized with myelin oligodendrocyte glycoprotein (MOG) were resistant

135 Although Abs to native myelin oligodendrocyte glycoprotein (MOG) were uncommon

136 zation of C57BL/6 mice with the neuroantigen myelin oligodendrocyte glycoprotein (MOG) with CFA, whic

137 o coadminister ITE and a T-cell epitope from myelin oligodendrocyte glycoprotein (MOG)(35)(-55) to pr

138 y (EAE) induced by immunization of mice with myelin oligodendrocyte glycoprotein (MOG)(35-55) Ig-like

139 he AhR agonist ITE and a T cell epitope from myelin oligodendrocyte glycoprotein (MOG)(35-55) induced

140 EAE, both mouse strains were sensitized with myelin oligodendrocyte glycoprotein (MOG)(35-55) peptide

141 The MHC variant peptide of myelin oligodendrocyte glycoprotein (MOG)(35-55) proves

142 ), yet IFN-gamma production is comparable to myelin oligodendrocyte glycoprotein (MOG)(35-55)-immuniz

143 , 2D2 cells were immediately stimulated with myelin oligodendrocyte glycoprotein (MOG)(35-55).

144 ped Foxp3gfp knock-in (Foxp3gfp.KI) mice and myelin oligodendrocyte glycoprotein (MOG)(35-55)/IA(b) (

145 disrupted Hrh4 (H(4)RKO) develop more severe myelin oligodendrocyte glycoprotein (MOG)(35\x{2013}55)-

146 Using myelin oligodendrocyte glycoprotein (MOG)(92-106), we ha

147 Myelin oligodendrocyte glycoprotein (MOG), a constituent

148 t are deficient in miR-146a and specific for myelin oligodendrocyte glycoprotein (MOG), an autoantige

149 Aggregated (agg) Ig-myelin oligodendrocyte glycoprotein (MOG), an Ig chimera

150 iredoxin 4 (Prdx4), stathmin-like 2 (Stmn2), myelin oligodendrocyte glycoprotein (MOG), and versican

151 tein levels of proteolipid protein (PLP) and myelin oligodendrocyte glycoprotein (MOG), the membrane

152 mice would process exogenously administered myelin oligodendrocyte glycoprotein (MOG), which contain

153 D-CM) inhibited the proliferation of murine myelin oligodendrocyte glycoprotein (MOG)-(35-55)-specif

154 ental autoimmune encephalomyelitis there are myelin oligodendrocyte glycoprotein (MOG)--specific Treg

155 In a previous study, we demonstrated that myelin oligodendrocyte glycoprotein (MOG)-35-55 peptide

156 severity than males after immunization with myelin oligodendrocyte glycoprotein (MOG)-35-55 peptide/

157 SD patients and also assessed their value in myelin oligodendrocyte glycoprotein (MOG)-ab positive an

158 Myelin oligodendrocyte glycoprotein (MOG)-Ab was detecte

159 Ab-seropositive, 3 double-Ab-seronegative, 4 myelin oligodendrocyte glycoprotein (MOG)-Ab-seropositiv

160 n using histological methods in chronic EAE [myelin oligodendrocyte glycoprotein (MOG)-induced diseas

161 lls diminishes the intensity and duration of myelin oligodendrocyte glycoprotein (MOG)-induced EAE an

162 (2) treatment diminishes progression of both myelin oligodendrocyte glycoprotein (MOG)-induced EAE in

163 nses and attenuates the clinical severity of myelin oligodendrocyte glycoprotein (MOG)-induced EAE wh

164 GAS6 directly into the CNS of WT mice during myelin oligodendrocyte glycoprotein (MOG)-induced EAE wo

165 cific SOCS3-deficient mice are vulnerable to myelin oligodendrocyte glycoprotein (MOG)-induced EAE, w

166 Rbeta1(-/-) mice are completely resistant to myelin oligodendrocyte glycoprotein (MOG)-induced EAE, w

167 antagonist naltrexone (LDN) on expression of myelin oligodendrocyte glycoprotein (MOG)-induced EAE.

168 matory bowel disease (IBD) and in a model of myelin oligodendrocyte glycoprotein (MOG)-induced experi

169 he central nervous system (CNS) of mice with myelin oligodendrocyte glycoprotein (MOG)-induced experi

170 's murine encephalomyelitis virus (TMEV) and myelin oligodendrocyte glycoprotein (MOG)-induced experi

171 tested the consequences of AhR activation in myelin oligodendrocyte glycoprotein (MOG)-induced experi

172 of Hrd1 function in DCs protected mice from myelin oligodendrocyte glycoprotein (MOG)-induced experi

173 -17, IL-6, IFN-gamma, and TNF-alpha, and the myelin oligodendrocyte glycoprotein (MOG)-induced IL-17,

174 Using a myelin oligodendrocyte glycoprotein (MOG)-induced model

175 Therefore, myelin oligodendrocyte glycoprotein (MOG)-specific autoa

176 reated transgenic (Tg) mice that express the myelin oligodendrocyte glycoprotein (MOG)-specific B cel

177 nate chemokine receptors CXCR3 and CXCR6 and myelin oligodendrocyte glycoprotein (MOG)-specific CD4(+

178 repeated antigenic stimulation of pathogenic myelin oligodendrocyte glycoprotein (MOG)-specific CD4(+

179 ne disease using the CD4(+) T cell-dependent myelin oligodendrocyte glycoprotein (MOG)-specific exper

180 In this study, we investigated whether myelin oligodendrocyte glycoprotein (MOG)-specific T cel

181 ased numbers of T lymphocytes in the CNS and myelin oligodendrocyte glycoprotein (MOG)-specific T cel

182 Serum from Myelin oligodendrocyte glycoprotein (MOG)-specific T cel

183 In the absence of CD137L, myelin oligodendrocyte glycoprotein (MOG)-specific T-cel

184 /fl) mice had a heightened capacity to prime myelin oligodendrocyte glycoprotein (MOG)-specific Th ce

185 receptor (TCR) transgenic mice specific for myelin oligodendrocyte glycoprotein (MOG).

186 ific for the immunodominant epitope 40-48 of myelin oligodendrocyte glycoprotein (MOG).

187 b)-immunodominant peptide of the autoantigen myelin oligodendrocyte glycoprotein (MOG).

188 for the tolerogenic vaccine Ag PLP178-191 or myelin oligodendrocyte glycoprotein (MOG)35-55 in proteo

189 (-/-) mice showed enhanced susceptibility to myelin oligodendrocyte glycoprotein (MOG)35-55 peptide-i

190 ely ameliorated clinical disease severity in myelin oligodendrocyte glycoprotein (MOG)35-55 peptide-i

191 T cells from myelin oligodendrocyte glycoprotein (MOG)35-55 peptide-p

192 lomyelitis (EAE) following immunization with myelin oligodendrocyte glycoprotein (MOG)35-55 peptide.

193 esistant to EAE induced by immunization with myelin oligodendrocyte glycoprotein (MOG)35-55 The mecha

194 responses to PLP139-151, but not PLP178-191, myelin oligodendrocyte glycoprotein (MOG)35-55, or OVA32

195 M knockout (KO) mice developed a more severe myelin oligodendrocyte glycoprotein (MOG)35-55-induced e

196 contribution of CD4(+) and CD8(+) T cells in myelin oligodendrocyte glycoprotein (MOG)35-55-induced E

197 for DEC205 and fused the scFv to the self-Ag myelin oligodendrocyte glycoprotein (MOG; scFv DEC:MOG).

198 of ON in C57BL/6 (B6) mice immunized with a myelin oligodendrocyte/glycoprotein (MOG)-derived peptid

199 Anti-myelin-oligodendrocyte glycoprotein (MOG) antibody produ

200 ns at 90 and 180 days post-EAE induction via myelin-oligodendrocyte glycoprotein (MOG) injection.

201 l setting, the significance of antibodies to myelin-oligodendrocyte glycoprotein (MOG) or the glycine

202 ays (CBA) for aquaporin-4 (AQP4)-M23-IgG and myelin-oligodendrocyte glycoprotein (MOG)-alpha1-IgG.

203 on of chronic EAE in NOD mice immunized with myelin-oligodendrocyte glycoprotein (MOG).

204 ogical disorders with IgG antibodies against myelin-oligodendrocyte glycoprotein (MOG-IgG) have been

205 Myelin/oligodendrocyte glycoprotein (MOG) is a target an

206 enhanced by addition of a peptide extension (myelin oligodendrocyte glycoprotein [MOG]-35-55 peptide)

207 to induce allogenic as well as Ag-specific (myelin oligodendrocyte glycoprotein [MOG]35-55) T cell r

208 n schizophrenia (myelin basic protein [MBP], myelin-oligodendrocyte glycoprotein [MOG], beta-actin [A

209 GM-CSF fused to the myelin oligodendrocyte glycoprotein MOG35-55 peptide (GM

210 addressed the functional role of TIMP-1 in a myelin oligodendrocyte glycoprotein (MOG35-55)-induced m

211 TCR beta-chain knockout (KO) recipients of a myelin oligodendrocyte glycoprotein p35-55 encephalitoge

212 Following immunization with myelin oligodendrocyte glycoprotein peptide (35-55), LIG

213 Inducing EAE by immunization with a myelin oligodendrocyte glycoprotein peptide (MOG(35-55))

214 In response to immunization with myelin oligodendrocyte glycoprotein peptide (MOG(35-55))

215 ined the effect of global CD44 deficiency on myelin oligodendrocyte glycoprotein peptide (MOG)-induce

216 s (EAE) produced by active immunization with myelin oligodendrocyte glycoprotein peptide (MOG).

217 d by active immunization with 100 micro g of myelin oligodendrocyte glycoprotein peptide (MOG)p35-55.

218 clinical symptoms of EAE induced in mice by myelin oligodendrocyte glycoprotein peptide (MOG35-55) i

219 In this study we report that myelin oligodendrocyte glycoprotein peptide (MOG35-55)-i

220 encephalomyelitis (EAE) by immunization with myelin oligodendrocyte glycoprotein peptide 35-55 (MOG p

221 induced in C57BL/6 mice by immunization with myelin oligodendrocyte glycoprotein peptide 35-55 (MOG p

222 licited in C57BL/6 mice by immunization with myelin oligodendrocyte glycoprotein peptide 35-55 (MOG-p

223 present study we show that immunization with myelin oligodendrocyte glycoprotein peptide 35-55 (MOG35

224 mmune encephalomyelitis (EAE), induced using myelin oligodendrocyte glycoprotein peptide 35-55 (MOG35

225 e to EAE induced with a peptide derived from myelin oligodendrocyte glycoprotein peptide 35-55 (MOGp3

226 d WY14,643 display impaired IgG responses to myelin oligodendrocyte glycoprotein peptide 35-55 (pMOG(

227 cytokine secretion of T cells to the self Ag myelin oligodendrocyte glycoprotein peptide 35-55 and to

228 In C57BL/6 mice immunized with myelin oligodendrocyte glycoprotein peptide 35-55 to dev

229 before induction of EAE with a neuroantigen, myelin oligodendrocyte glycoprotein peptide 35-55, and a

230 6 mice with EAE induced by immunization with myelin oligodendrocyte glycoprotein peptide 35-55, the f

231 h wild-type mice following immunization with myelin oligodendrocyte glycoprotein peptide 35-55, while

232 al autoimmune encephalomyelitis induced with myelin oligodendrocyte glycoprotein peptide 35-55.

233 d their wild-type (C3(+/+)) littermates with myelin oligodendrocyte glycoprotein peptide 35-55.

234 induced by immunization of C57BL/6 mice with myelin oligodendrocyte glycoprotein peptide 35-55.

235 yk2(A)) and B10.Q/Ai (Tyk2(G)) mice with the myelin oligodendrocyte glycoprotein peptide 79-96.

236 ronic disease in C57BL/6 mice immunized with myelin oligodendrocyte glycoprotein peptide and of relap

237 We found that myelin oligodendrocyte glycoprotein peptide immunization

238 T cells following immunization of mice with myelin oligodendrocyte glycoprotein peptide in complete

239 rom IFN-alpha-treated mice re-exposed to the myelin oligodendrocyte glycoprotein peptide in vitro sho

240 ion of CD44(+) encephalitogenic T cells with myelin oligodendrocyte glycoprotein peptide led to demet

241 14, 21 or 35 days after vaccination with the myelin oligodendrocyte glycoprotein peptide MOG(35-55).

242 ugh the use of primary immunization with the myelin oligodendrocyte glycoprotein peptide to induce ex

243 se, adoptive transfer of B cells pulsed with myelin oligodendrocyte glycoprotein peptide(35-55) (MOGp

244 mponent in C activation, is not essential in myelin oligodendrocyte glycoprotein peptide-induced EAE

245 te that targeted deletion of CD44 attenuated myelin oligodendrocyte glycoprotein peptide-induced expe

246 ) to explore these issues in adult mice with myelin oligodendrocyte glycoprotein peptide-induced expe

247 e, the mice were significantly less prone to myelin oligodendrocyte glycoprotein peptide-induced expe

248 However, myelin oligodendrocyte glycoprotein peptide-specific CD4

249 nd to alter immune adaptive responses to the myelin oligodendrocyte glycoprotein peptide.

250 r EAE induced by a myelin basic protein or a myelin oligodendrocyte glycoprotein peptide.

251 rd after immunization of mice with MOG35-55 (myelin oligodendrocyte glycoprotein) peptide.

252 After immunization with myelin oligodendrocyte glycoprotein-peptides, GF-IL-12 m

253 we report that synthetic peptides 35-55 from myelin oligodendrocyte glycoprotein (pMOG(35-55)) consis

254 majority of CNS-infiltrating CD4 T cells are myelin oligodendrocyte glycoprotein reactive at all time

255 highest affinity and frequency of polyclonal myelin oligodendrocyte glycoprotein-reactive cells infil

256 cient mice, showing a profound defect in the myelin oligodendrocyte glycoprotein-reactive T cell popu

257 a and interleukin-4 production by pathogenic myelin oligodendrocyte glycoprotein-reactive T cells.

258 f encephalitogenic cytokines by the targeted myelin oligodendrocyte glycoprotein-reactive T-cells but

259 eeding low doses of 0.5 mg OVA or 250 microg myelin oligodendrocyte glycoprotein resulted in up-regul

260 utaneous immunization with recombinant human myelin oligodendrocyte glycoprotein (rhMOG) in CFA on da

261 Murine EAE was induced by recombinant myelin oligodendrocyte glycoprotein (rMOG), a model in w

262 We previously generated myelin oligodendrocyte glycoprotein-specific (MOG-specif

263 spontaneous autoimmune CNS demyelination in myelin oligodendrocyte glycoprotein-specific 2D2 TCR tra

264 ally elevated plasma cell numbers and higher myelin oligodendrocyte glycoprotein-specific Ab levels d

265 Myelin oligodendrocyte glycoprotein-specific Abs and sho

266 o suppress IFN-gamma and IL-17 production by myelin oligodendrocyte glycoprotein-specific CD4(+) T ce

267 Interestingly, B7-H1 ablation on myelin oligodendrocyte glycoprotein-specific CD4(+) T ce

268 deficiency resulted in a severely diminished myelin oligodendrocyte glycoprotein-specific CD4+ T cell

269 28+ T cells suppress IFN-gamma production of myelin oligodendrocyte glycoprotein-specific CD4+ T cell

270 vivo, we cotransferred these antibodies with myelin oligodendrocyte glycoprotein-specific encephalito

271 lso applicable in autoimmune disease because myelin oligodendrocyte glycoprotein-specific Foxp3(+) T

272 s a significant decrease in the frequency of myelin oligodendrocyte glycoprotein-specific IFN-gamma-p

273 induced protection of EAE and suppression of myelin oligodendrocyte glycoprotein-specific IL-17(+)CD4

274 d B cells as well as increased production of myelin oligodendrocyte glycoprotein-specific IL-17, IFN-

275 show that CD4(+)CD25(+)LAP(+) cells suppress myelin oligodendrocyte glycoprotein-specific immune resp

276 In this article, we demonstrate that myelin oligodendrocyte glycoprotein-specific Kv1.3-KO Th

277 Moreover, myelin oligodendrocyte glycoprotein-specific Kv1.3-KO Th

278 Myelin oligodendrocyte glycoprotein-specific T cell prol

279 Although increased myelin oligodendrocyte glycoprotein-specific T cell reac

280 served when Tob1(-)/(-) mice were crossed to myelin oligodendrocyte glycoprotein-specific T cell rece

281 rvival; accordingly, ASC(-/-) mice had fewer myelin oligodendrocyte glycoprotein-specific T cells in

282 study, we showed that highly purified CD8(+) myelin oligodendrocyte glycoprotein-specific T cells ind

283 ctionally, SOCS-3-transduced DCs drove naive myelin oligodendrocyte glycoprotein-specific T cells to

284 n the CNS during EAE, are highly enriched in myelin oligodendrocyte glycoprotein-specific T cells.

285 D4-Cre and crossed these with mice bearing a myelin oligodendrocyte glycoprotein-specific TCR transge

286 led to induce EAE after adoptive transfer of myelin oligodendrocyte glycoprotein-specific TCR-transge

287 gment TCR affinity, which we studied using a myelin oligodendrocyte glycoprotein-specific TCR.

288 By contrast, myelin oligodendrocyte glycoprotein-specific Th1 and Th2

289 We show that myelin oligodendrocyte glycoprotein-specific Th1, Th17,

290 ere, we have developed protocols to generate myelin oligodendrocyte glycoprotein-specific Th17, Th1,

291 lso enhanced their costimulatory activity to myelin oligodendrocyte glycoprotein-specific, TCR-transg

292 ls from C57BL/6J mice activated in vivo with myelin oligodendrocyte glycoprotein, Staphylococcal ente

293 ntral nervous system (CNS)-specific antigen, myelin oligodendrocyte glycoprotein, that usually develo

294 in oral tolerance we fed low doses of OVA or myelin oligodendrocyte glycoprotein to B cell-deficient

295 , presentation to primary T cells of OVA and myelin oligodendrocyte glycoprotein, two Ags that contai

296 eration in vivo, we targeted a self antigen, myelin oligodendrocyte glycoprotein, using antibodies ag

297 ainst aquaporin 4 and high-titer Abs against myelin oligodendrocyte glycoprotein were, as expected, s

298 , such as proteolipid protein, MAG, MBP, and myelin oligodendrocyte glycoprotein, were rapidly downre

299 another oligodendrocyte-specific component, myelin oligodendrocyte glycoprotein, which is expressed

300 ate antigens such as myelin basic protein or myelin-oligodendrocyte glycoprotein, with inconclusive r